Cryopyrin-Associated Periodic Syndrome (CAPS) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2022 To 2032


 Cryopyrin-associated Periodic Syndrome (CAPS) is a group of autoinflammatory disorders characterized by recurrent episodes of systemic inflammation. It comprises 3 distinct disorders that vary in severity: CINCA, Muckle-Wells, and familial cold urticaria. These disorders are caused by mutations in the NLRP3 gene, which encodes for the protein cryopyrin. These mutations result in a gain of function of cryopyrin, leading to increased secretion of IL-1 beta and dysregulated inflammation. The clinical presentation of CAPS can vary among patients with identical mutations. Differential diagnoses include systemic-onset juvenile idiopathic arthritis, rheumatoid arthritis, and systemic lupus erythematosus. The most effective treatment is IL-1 blockade using anakinra, rilonacept, or canakinumab. With optimal treatment adjustments, the progression of hearing loss and vision loss can be halted in most patients.

·       The prevalence in France is estimated to be 1 per 360,000. Males and females are equally affected.

Thelansis’s “Cryopyrin-Associated Periodic Syndrome (CAPS) Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2022 To 2032" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Cryopyrin-Associated Periodic Syndrome (CAPS) treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).

KOLs insights of Cryopyrin-Associated Periodic Syndrome (CAPS) across 8 MM market from the centre of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm, and Unmet needs.

Cryopyrin-Associated Periodic Syndrome (CAPS) Market Forecast Patient Based Forecast Model (MS. Excel Based Automated Dashboard), which Data Inputs with sourcing, Market Event, and Product Event, Country specific Forecast Model, Market uptake and patient share uptake, Attribute Analysis, Analog Analysis, Disease burden, and pricing scenario, Summary, and Insights.

Thelansis Competitive Intelligence (CI) practice has been established based on a deep understanding of the pharma/biotech business environment to provide an optimized support system to all levels of the decision-making process. It enables business leaders in forward-thinking and proactive decision-making. Thelansis supports scientific and commercial teams in seamless CI support by creating an AI/ ML-based technology-driven platform that manages the data flow from primary and secondary sources.

Read more: Cryopyrin-Associated Periodic Syndrome (CAPS) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2022 To 2032

Comments

Popular posts from this blog

Acne Vulgaris – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2022 To 2032

Metabolic Syndrome – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033

Type 1 Diabetes Mellitus (T1D) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033